CDK inhibitors may boost the effectiveness of immune therapy in metastatic breast cancer
A class of drugs that inhibits breast cancer progression when used with hormonal therapy might also boost the effectiveness of immune therapy in cases of recurrent, metastatic breast cancer, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).
Published in the journal
Cell Reports, the findings of the animal study suggest that drugs called CDK4 and CDK6 (CDK4/6) inhibitors might improve the effectiveness of immune therapies for metastatic, estrogen-receptor-positive (ER+) breast cancer.
E-Mail
COLUMBUS, Ohio - The symptoms of grief people feel for a loved one facing a life-limiting illness fluctuate over time, a new study found - suggesting that individuals can adjust to their emotional pain, but also revealing factors that can make pre-loss grief more severe.
Researchers examined changes in the severity of pre-loss grief symptoms in people whose family members had either advanced cancer or dementia.
The study is the first to document pre-loss grief at two points in time, and found that about 70% of participants symptoms decreased over a month. However, compared to initial symptoms reported by participants, women and those with a heavy caregiving burden were more likely to be experiencing more intense symptoms a month later.
Date Time
Study looks at factors that influence pre-loss grief
COLUMBUS, Ohio – The symptoms of grief people feel for a loved one facing a life-limiting illness fluctuate over time, a new study found – suggesting that individuals can adjust to their emotional pain, but also revealing factors that can make pre-loss grief more severe.
Researchers examined changes in the severity of pre-loss grief symptoms in people whose family members had either advanced cancer or dementia.
The study is the first to document pre-loss grief at two points in time, and found that about 70% of participants’ symptoms decreased over a month. However, compared to initial symptoms reported by participants, women and those with a heavy caregiving burden were more likely to be experiencing more intense symptoms a month later.
Recurrent, metastatic breast cancer resists treatment and is usually fatal. These tumors often have low numbers of immune cells in them, which renders immune therapies less effective for the disease. This preclinical study suggests that drugs called CDK4 and CDK6 inhibitors may make immune-cell therapies an effective option for treating recurrent ER-positive metastatic breast cancer.
COLUMBUS, Ohio - A class of drugs that inhibits breast cancer progression when used with hormonal therapy might also boost the effectiveness of immune therapy in cases of recurrent, metastatic breast cancer, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).
Ohio State University study retrains cells to reverse brain damage from stroke ktbs.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ktbs.com Daily Mail and Mail on Sunday newspapers.